|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Gal-1 expression was also correlated with biomarkers of the tumor microenvironment.
|
31834627 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The authors demonstrated that Gal1 can affect immune checkpoint inhibitor therapy by increasing immune checkpoint molecules and immunosuppressive signaling in the tumor.
|
31710312 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Inhibition of human Gal-1 has been regarded as one of the potential therapeutic approaches for the treatment of cancer, as it plays a major role in tumour development and metastasis by modulating various biological functions viz. apoptosis, angiogenesis, migration, cell immune escape.
|
30834831 |
2019 |
|
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
Expert commentary: GALR studies have highlighted two major aspects with implications in HNSCC - that G-protein coupled receptors (GPCRs) act as tumor suppressor genes and that GALR promoter methylation is significantly related to the carcinogenesis of HNSCC.
|
30640567 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Distribution Patterns of Cocaine- and Amphetamine-Regulated Transcript- and/or Galanin-Containing Neurons and Nerve Fibers Located in the Human Stomach Wall Affected by Tumor.
|
30373200 |
2018 |
|
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
Taken together, these data suggest that galanin hypermethylation impairs its tumor suppressor function in gastric cancer carcinogenesis.
|
29462183 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Additionally, galanin had no effect on the hemoglobin content of tumors derived from cells lacking GALR2.
|
29123986 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Gal-1 expression and T cell apoptosis were evaluated in 6 high-power fields (3 in the tumour and 3 in the stroma).
|
28108653 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Galanin is a neuropeptide with a widespread distribution throughout the nervous and endocrine systems, and recent studies have shown an anti-proliferative effect of galanin on several types of tumors.
|
28525358 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We were able to show that both tumor and stroma staining of Gal-1 could serve as negative prognostic factors for ovarian cancer.
|
28594391 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
To determine the prognostic value of GAL, GALR1 and GALR2 methylation status, their associations with various clinical characteristics and patient survival were assessed in HNSCC patient tumors (n = 142).
|
26572146 |
2016 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
SSTR1 hypermethylation in 64% of cases was correlated with tumor size (P = 0.037), stage (P = 0.037), SST methylation (P < 0.001), and expression of galanin (P = 0.03), GALR2 (P = 0.014), TAC1 (P = 0.023), and tachykinin receptor type 1 (TACR1) (P = 0.003).
|
25734919 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
OSCC patients expressed significantly higher levels of gal-1 and gal-3 in circulation (p<0.0001) and at the tumour sites (p<0.01) as compared to controls.
|
25578395 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We compared GAL expression between 56 patients with stage II and III CRC who developed tumor recurrences and 56 patients who did not.
|
25504183 |
2015 |
|
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
GALR2 methylation found in 31 of 100 (31.0%) tumor specimens was significantly correlated with the methylation status of both GALR1 and Galanin.
|
24122450 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Here, we show that Gal-1 expression strongly correlates with tumor growth rate, metastatic capacity and response to single-dose Cy therapy in T-cell lymphoma models; this association might have important consequences for evaluating prognosis and treatments of this type of tumors.
|
21947259 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Conversely, gel filtration chromatography analysis of tumor extracts from SBC-3A, BT-549 and MDA-MB-436-bearing mice, revealed that galanin-like immunoreactivity (galanin-LI) in these tumor extracts was due to the presence of progalanin (14 kDa) and galanin(1-20) (2 kDa).
|
21707521 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Contradictory roles for galanin and its receptors in various tumors have been reported.
|
19276245 |
2009 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The galanin expression level was significantly increased with tumor size and tumor stage.
|
18006926 |
2007 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Gal-1(hi) expression was associated with male gender, older patients, reduced CD8(+) T cell infiltration at the tumor site, and most importantly, an impaired latent membrane protein 1 and 2-specific CD8(+) T-cell responses.
|
17438085 |
2007 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In neuroblastic tumors a relationship of differentiation of the tumor to galanin receptor expression and antiproliferative and apoptotic effects upon activation of galanin receptors in neuroblastoma cells was reported.
|
16954604 |
2006 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
When Colo320 HRS cells were treated with rAd5-R1, before injection into CD-1 mice, there was complete inhibition of tumor growth compared with treatment with rAd5-LacZ.
|
14555530 |
2003 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Pharmacological analysis of tumor membrane homogenates with GAL and the specific GAL receptor GalR2 agonist, AR-M1896, revealed that the GAL receptor GalR1 is most likely the receptor responsible for the observed GAL binding in the glioblastomas.
|
12734662 |
2003 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
GAL peptide concentrations up to 674 +/- 166 fmol/mg of tissue were detected by radioimmunoassay, but no significant correlation with standard tumor markers or the prognosis of the 14 patients investigated was observed.
|
11867941 |
2002 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Neuropeptides like galanin produced and released by small cell lung cancer (SCLC) cells are considered principal mitogens in these tumors.
|
10980593 |
2000 |